Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of KT-333, a Targeted Protein Degrader of STAT3, in Patients with Relapsed or Refractory Lymphomas, Leukemia, and Solid Tumors

Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of KT-333, a Targeted Protein Degrader of STAT3, in Patients with Relapsed or Refractory Lymphomas, Leukemia, and Solid Tumors

American Society of Hematology (ASH) 2024

Tatyana Feldman, MD, Enrica Marchi, MD, PhD, Stephen D Smith, MD, Adam J. Olszewski, MD, Auris O Huen, MD, PharmD, Zachary D. Epstein-Peterson, MD, Don A. Stevens, MD, Alexander N. Starodub, MD, Eric J. Feldman, MD, Cristina P Rodriguez, MD, John C. Reneau, MD, PhD, Jonathan E. Brammer, MD, Ahmad H. Mattour, MD, Lauren C. Pinter-Brown, MD, FACP, Rachelle Perea, Patrick Henrick, BS, Joyoti Dey, PhD, MPH, Alyssa Fasciano, PhD, Rahul Karnik, PhD, Sagar Agarwal, PhD, Victoria Bainer, Ashwin Gollerkeri, MD, Jared Gollob, MD, Aditi Shastri, MD and Stefan K. Barta, MD